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ABSTRACT 
 
Introduction: During exercise training, an increase in insulin sensitivity is accompanied by 
a decrease in plasma insulin concentrations during an oral glucose tolerance test (OGTT).  
The purpose of this study was to investigate the role incretin hormones play in the blunted 
insulin release after exercise.  Gastric inhibitory polypeptide (GIP) and Glucagon-like 
peptide-1 (GLP-1) are incretin hormones that cause insulin release after glucose ingestion.  
We hypothesized that insulin, GLP-1, and GIP concentrations during an OGTT would be 
lower after exercise compared to after 7 days of inactivity.   
Methods: Nine healthy men (n = 5) and women (n = 4) currently engaged in endurance 
exercise (23 ± 2 y) underwent 5 d of exercise at ~75% VO2peak for 60 min.  An OGTT was 
performed immediately post-exercise (IPE), one day after exercise (Day 1), and one week 
later (Day 7).  Subjects were inactive between Day 1 and Day 7 (no exercise exceeding the 
intensity of activities of daily living).   
Results: No change in body mass or body composition occurred during the study period.  
Glucose area under the curve (mmol/L x min) was significantly lower (P < 0.05) on Day 1 
(160 ± 65) compared with IPE (233 ± 65) and was similar on Day 7 (186 ± 94).  Although 
insulin sensitivity, as calculated by insulin-glucose index (pmol/L · min x mmol/L · min x 
104), did not reach significance between Day 1 (569 ± 328) and Day 7 (1,023 ± 810), the 
plasma insulin response curve was significantly higher during the Day 7 OGTT compared 
with IPE (P < 0.05).  Similarly, plasma GIP concentrations during the Day 7 OGTT were 
significantly higher than Day 1 (P < 0.05).  No differences occurred within GLP-1 areas or 
OGTT responses. 
 vi
Discussion:  These data suggest that GIP and GLP-1 do not play significant roles in the 
blunted insulin release after exercise.  The mechanism for the blunted insulin response may 
be important for furthering treatment of Type 2 diabetes and should continue to be studied, 
perhaps by focusing on other factors from the gut that influence insulin secretion. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
Immediately after exercise, higher plasma glucose and insulin responses during a 75-g oral 
glucose tolerance test suggest impairment in insulin sensitivity (41).  Within 10-16 h, the 
relative insulin resistance is followed by improved insulin sensitivity and glucose tolerance.  
This improved insulin action appears to last for three, but not 5 days (41). 
 Although the mechanism for a lower insulin secretion in response to glucose after 
exercise is unclear, there are factors in addition to glucose that stimulate the release of 
insulin from the pancreas.  Increases in plasma amino acid concentrations, fat ingestion, and 
the release of gut hormones have all been shown to stimulate insulin release (44, 83, 86).  
Two gut hormones that elicit the incretin effect are Glucagon-like Peptide-1 (GLP-1) and 
Gastric inhibitory polypeptide (also referred to as Glucose-dependent insulinotropic 
Peptide, or GIP).   
The importance of gut hormones in modifying insulin release became clear after it 
was noted that oral glucose administration causes a higher insulin response compared to an 
intravenous glucose infusion (61, 78).  Shuster and others (78) found that insulin secretion, 
C-peptide, and GIP were all significantly higher in response to oral glucose ingestion 
compared to intravenous infusion in normal subjects with the same basal plasma glucose.  
The lower insulin response as a result of exercise is also more pronounced with oral glucose 
administration. 
The insulin responses to glucose, arginine, and fat ingestion are all blunted in 
endurance trained people (44).  Although the plasma insulin concentrations continued to 
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rise when intake of fat was combined with glucose and amino acid infusion, and fat 
ingestion, the plasma concentration of GIP decreased suggesting other factors regulating the 
release of insulin. Perhaps other gut hormones such as GLP-1 are responsible for the 
reduced release of insulin in endurance trained people. 
 Few studies have investigated the gut hormones response to exercise.  An early 
study on GIP demonstrated lower plasma concentrations of GIP after exercise compared to 
non-exercised individuals in response to glucose ingestion (9).  O’Connor and colleagues 
(64) detected increases in plasma GLP-1 during and after a 120 minute running bout.  De 
Luis et al. (16) found resting GLP-1 levels to decrease after weight loss induced by physical 
activity and hypocaloric diet.  Previous literature on GIP indicates that significant changes 
in GIP levels do not occur during and after exercise (33, 36, 64).  Because of the limited 
research on GLP-1 and GIP related to exercise training and the blunted response of insulin, 
it was the purpose of this study to investigate the role of the gut hormones in the blunted 
insulin response after exercise.  We hypothesized that plasma gut hormone concentrations 
will be significantly higher seven days after cessation of exercise compared to immediately 
after exercise and one day after exercise similar to the trend of insulin concentrations. 
 
 
Thesis Organization 
This thesis is organized into a General Introduction, Manuscript, and General Conclusions. 
The manuscript is formatted according to the Journal of Applied Physiology specifications.  
The primary author for this paper is Alison R. Glidden, a Master’s student in the 
Kinesiology department at Iowa State University.  Dr. Douglas S. King, a Professor of 
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Kinesiology at Iowa State University, contributed to the experimental design, data analysis, 
and preparation of the manuscript. 
 
Review of Literature 
Introduction 
Insulin has many metabolic roles, most importantly to regulate glucose homeostasis.  
Regulating and maintaining normal glucose levels is imperative in preventing metabolic 
diseases, namely diabetes mellitus (35).  The concept of exercise-induced insulin sensitivity 
with improved glucose tolerance has shed light on the importance of physical activity in 
treating and preventing disease (43).  The mechanism responsible for the decrease in insulin 
secretion in response to exercise is still unclear.  Factors that contribute to the release of 
insulin include blood glucose concentrations, plasma amino acid concentrations, fatty acids, 
catecholamines, the nervous system, and gut hormones.  The interest in gut hormones on 
their effect on insulin secretion became heightened after the discovery of the incretin effect.  
The incretin effect demonstrates that oral glucose ingestion elicits a higher insulin response 
compared to intravenous infusion of glucose (78). This review focuses on the stimulation of 
insulin release by two incretins, glucagon-like peptide-1 (GLP-1) and gastric inhibitory 
polypeptide (glucose-dependent insulinotropic peptide or GIP).  
 
Insulin and Disease 
Insulin is a hormone secreted from the pancreas to help regulate levels of blood glucose by 
causing glucose uptake into cells of the muscle, adipose, and liver.  Insulin also helps to 
regulate fat and protein synthesis and without normal functioning of insulin to regulate its 
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effects on metabolism, disorders such as diabetes mellitus, hyperlipidemia, metabolic 
syndrome, and obesity can appear (35).  The most common metabolic disorder is diabetes 
with diabetes mellitus (Type 2 diabetes) being the most common form of diabetes.  Type 2 
diabetes is characterized by a cellular resistance to insulin, meaning that although the 
pancreas is secreting insulin, the cells are not responding and therefore the metabolic effects 
of insulin are not taking place (24).  The effects of diabetes mellitus can also occur as a 
result of worse insulin secretion in response to glucose.  The ability of insulin to function 
effectively (characterized by insulin resistance and sensitivity) can be measured with an 
Oral Glucose Tolerance Test (OGTT) which can then be used to diagnose disorders such as 
diabetes mellitus (38).  An OGTT consists of giving 75 g of glucose and monitoring plasma 
glucose levels for the three hours following ingestion.  If plasma glucose concentrations 
exceed normal levels (at one hour, above 200 mg/dl; at two hours, above 140 mg/dl), 
impaired glucose tolerance is suspected (1).   
Recently, the incretins have become an important topic of study with a potential to 
help treat Type 2 diabetics because diabetic patients have a reduced incretin effect (61) and 
the hormones have an important contribution to the enteroinsular axis to regulate blood 
glucose homeostasis.  Because of problems with incretin degradation in the blood, two 
main therapeutic strategies are under clinical investigation and trial.  The first possible 
therapy is using receptor agonists or incretin mimetics (27).  A GLP-1 mimetic, exenatide is 
found naturally occurring in the Gila monster and has been shown to produce similar effects 
as GLP-1 while being resistant to the enzyme dipeptidyl peptidase IV (DPP IV) that breaks 
down the incretins.  The second idea of therapy aims to inhibit the DPP IV enzyme which 
rapidly breaks down the incretins into their noninsulinotropic metabolites (17, 20, 21).  The 
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DPP IV inhibitor has shown hints of preserving endogenous incretin activity, however the 
long term affects of DPP IV inhibitors is unknown.  The DPP IV enzyme is linked to 
inhibition of tumor growth  and therefore inhibition of this enzyme may lead to progression 
of cancer (50, 71, 89).  As noted, insulin and its stimulators are important hormones for 
metabolic regulation and therefore it is important to understand all components related to 
their regulation. 
 
Pancreas Physiology 
The pancreas has two types of cells (endocrine and exocrine) that connect to form an organ 
located on the dorsal and ventral side of the duodenum.  The exocrine cells are composed of 
acinar and ductal cells and function to release and transport digestive enzymes into the 
small intestine.  The endocrine cells form the islets of Langerhans and function to regulate 
glucose homeostasis (88).  There are roughly one million islets of Langerhans (4, 67) in a 
human adult and each islet consists of approximately two thousand cells.  Four different 
types of cells are contained within each islet being the alpha (α) cell secreting glucagon, the 
beta (β) cell secreting insulin, delta (δ) cells secreting somatostatin, and the pancreatic 
polypeptide (F) cells secreting pancreatic polypeptide (PP).  Each hormone has its own 
specific purpose when secreted into the circulation, but controlled by their regulatory 
mechanisms together make up the hormonal milieu that regulates glucose homeokinesis.  
Some regulation of the hormones of the endocrine pancreas is done by cell-to-cell 
interaction (45, 58).  Somatostatin’s role in regulation is inhibiting both insulin and 
glucagon secretion.  An example of this cell-to-cell regulation is the delta-to-beta cell axis 
in which somatostatin is released from the delta cell into the circulation around the islet and 
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reaches the somatostatin receptor on the beta cell to inhibit insulin secretion.  This type of 
regulation is thought to occur throughout the endocrine axis of the pancreatic islets (45).  
Effects of the other hormones of this axis include glucagon functioning to stimulate insulin 
and PP secretion and inhibit somatostatin while insulin acts to decrease glucagon and 
stimulate somatostatin (58). 
  
Insulin Synthesis and Release 
Insulin begins as a single polypeptide chain called preproinsulin located on the ribosomes 
in the cytosol of the beta-cell.  A signal peptide (N-terminal) sends the growing amino acid 
chain into the rough endoplasmic reticulum (RER) for preparation for secretion (84).  In the 
RER, the signal peptide is removed forming proinsulin to be transported to the Golgi 
apparatus.  By moving through the Golgi apparatus (and packaged into forming β-granules 
from sections of cisternae enclosing the proinsulin) proinsulin is converted to insulin and C-
peptide.  The cleavage of proinsulin to form insulin and C-peptide is completed with the 
help of proprotein-converting endopeptidases which allow for removal of amino acids to 
form an insulin molecule with its α− and β−chain aligned and C-peptide to become the 
lumen of a mature β-granule (66) and ending in an individual secretory granule.  The 
contents of a mature granule are either released from the β-cell via exocytosis when 
stimulated by factors that encourage insulin release or degraded after some time via 
crinophagy or autophagy (75).   
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Insulin Stimulation 
Substances including amino acids, fatty acids, and hormones stimulate insulin secretion; 
however glucose is the main factor to control insulin release (30).  Glucose stimulates the 
release of insulin from the β-cell when it is metabolized by the mitochondria (46).  The 
metabolism of glucose causes changes in the ratio of adenosine triphosphate (ATP) to 
adenosine diphosphate (ADP).  The increase in this ratio leads to closure of the cell 
membrane’s ATP-sensitive potassium (K+) channels thus causing membrane depolarization 
and the opening of the voltage-dependent calcium channels (VDCC).  The channels open 
creating an influx of intracellular calcium (Ca2+) which triggers insulin secretion and plays 
an important role in fueling insulin secretion (5).  Two hormones from the gut that stimulate 
insulin release are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like 
peptide-1 (GLP-1).  These hormones initiate insulin secretion by binding to their receptors 
on the β-cell membrane which activate cyclic AMP (cAMP) levels to turn on cAMP-
dependent protein kinase (PKA).  The receptors are coupled to Gs-proteins and activation of 
PKA leads to the production of second messenger pathways to increase Ca2+ concentrations 
(80).  The influx of Ca2+ through the VDCC causes insulin secretion from vesicles via 
exocytosis.  Insulin may also be secreted due to phosphorylation of vesicular proteins by 
PKA (39).  This abbreviated processes described here, however, does not account for the 
entire regulatory physiological steps required to induce insulin release, and exact 
mechanisms are still being investigated.  Hormones and catecholamines such as 
norepinephrine inhibit insulin secretion in much the same way as stimulators.  They bind to 
receptors that are coupled to Gi/o-proteins that inhibit adenylyl cyclase which alter the 
channels of K+ and Ca2+ (76).  Insulin secretion is also influenced by the autonomic nervous 
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system (especially during the cephalic phase of nutrient ingestion) (3) with the 
parasympathetic branch releasing acetylcholine to increase activity of M3 receptors (which 
are coupled to Gq-proteins) to potentiate insulin release and the sympathetic branch 
releasing epinephrine to inhibit insulin secretion (87). 
  
GLP-1 and GIP Physiology 
The role hormones play to regulate insulin release became evident after the relationship 
between the gastrointestinal tract and the pancreas became evident. A higher elicited 
response of insulin was discovered when glucose is ingested orally compared to the same 
amount infused intravenously.  The concept gave rise to what is known as the incretin effect 
with two gut hormones responsible for this, GIP and GLP-1 (28).  The gut hormones are in 
the glucagon peptide family.  The hormone GIP is formed within the intestinal K cells from 
a protein precursor (proGIP) made of a signal peptide, an N-terminal peptide, GIP, and a C-
terminal peptide.  Cleavage at the arginine on each side of the GIP forms a biologically 
active 42 amino acid peptide (85) which is released from the K cells located in the 
duodenum and proximal jejunum with small amounts also through the entire small intestine 
(59).  The formation and cleavage of the proglucagon gene produces glucagon and major 
proglucagon-derived fragment (MGPF) in the α-cells and GLP-1, GLP-2, and glicentin in 
the L cells of the ileum and colon.  After the translational release of GLP-1, the 30 amino 
acid peptide is released from the L cells of the ileum and colon (25) as well as from parts of 
the central nervous system including the hypothalamus, pituitary, and the reticular nucleus.   
Release of GIP and GLP-1 is stimulated by oral nutrient ingestion of fat and 
carbohydrate and by proteins for GLP-1 only (32) and contact of the peptides with the 
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intestinal mucosa is also adequate to cause release of the hormones from their 
corresponding cells.  Lipid ingestion stimulating the incretins release is supported in a dose-
dependent relationship (91) with GLP-1 tending to have a greater sensitivity to intraluminal 
lipid content.  Inhibition of both peptides has been shown after release of somatostatin 
release from nearby δ-cells via a paracrine interaction within the gut (17).  GIP has also 
been shown to be stimulated by the autonomic nervous system (3), sympathetic nervous 
system (β-adrenergic stimulation) (26), glutamine, cAMP, and phorbol 12-myristate 13-
acetate (PMA) (69) while α-2 adrenergic activation was shown to decrease GIP levels (73). 
A negative feedback mechanism of GIP was also evident when an increase in hypothalamic 
insulin levels decreased the release of GIP after a glucose load (90). GLP-1 release can be 
stimulated by neural control as well (via activation of vagal cholinergic muscarinic 
receptors and β-adrenergic receptors), and by GIP, acetycholine, neuromedin C (64), and 
Gastrin-Releasing Peptide (GRP) (13) and GLP-1 is inhibited by sympathetic efferents, or 
α-2 receptors (34).   
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Table 1. Summary of factors influencing incretin release. 
 
 
GIP Release GLP-1 Release 
     Stimulate                      Inhibit           Stimulate                       Inhibit 
Nutrient: 
 
 
 
 
 
 
Fat and CHO 
presence on lumen 
 
Protein (animals 
only) 
 
Glutamine 
 
phorbol 12-
myristate 13-
acetate (PMA) 
 Fat, CHO, Protein 
presence on lumen 
 
Plasma glucose (after 
oral ingestion only) 
 
Hormonal: 
 
 
Gastrin-releasing 
peptide 
 
Somatostatin 
 
GIP (high 
concentrations only) 
 
Acetylcholine 
 
Gastrin-releasing 
peptide 
 
Somatostatin 
Neural: 
 
 
β-2 adrenergic 
receptors 
 
α-2 
adrenergic 
receptors 
β-2 adrenergic 
 
α-1 receptors 
 
vagal cholinergic 
muscarinic (M3) 
receptors 
 
α-2 
adrenergic 
receptors 
 
 
Other: cAMP (calcium 
dependent) 
 cAMP (calcium  
dependent) 
 
Neuromedin C 
 
 
 Once released from their corresponding cells, GIP and GLP-1 both break down 
rapidly.  The enzyme dipeptidyl peptidase IV (DPP IV) cleaves the N-terminal of both 
hormones indicated in vitro (55) and in vivo (20).  The abundance of DPP IV deriving 
locations include the kidney, intestinal brush border membranes, hepatocytes, and 
throughout the vascular bed (54) causing the incretins to be broken down rapidly with a 
plasma half-life of exogenous GIP shown to be about 7 minutes while the half-life of 
exogenous GLP-1 is as short as 1 to 2 minutes (52).  More importantly, endogenous 
hormones are more rapidly degraded (particularly GLP-1) as DPP IV is found in the 
endothelium of the capillaries neighboring the L-cells causing more than half of GLP-1 to 
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be degraded before it even enters systemic circulation (29).  The degradation of both 
exogenous (18, 19) and endogenous (7) GIP and GLP-1 has been shown to be successfully 
repressed with the presence of DPP IV inhibitors which can adequately preserve the effects 
of the hormones (21). 
 
Role of GIP and GLP-1 on Insulin Secretion 
Although GIP and GLP-1 have various functions as hormones, their role promoting insulin 
secretion is one of the most important.  Both peptides are glucose-dependent in their 
insulin-secreting effects and use a similar pathway to cause insulin secretion.  The 
intracellular pathway utilizes Gs protein-coupled receptors for GIP and GLP-1 on the β-cell 
that are activated to initiate a rise in adenylyl cyclase activity and cAMP leading to an 
increase in PKA activity and intracellular Ca2+ concentrations and ultimately insulin release 
via exocytosis (22, 47, 72).  The influences of GIP and GLP-1 have been verified with 
studies in rats with either missing GLP-1 or GIP receptors or when administering the 
peptide receptor antagonist to prevent the influence of the hormones on insulin release.  
After nutrient ingestion, the results of insulin release were analyzed and indicated 
attenuated insulin secretion resulting in hyperglycemia and glucose intolerance (25, 57, 70).   
The incretins have also been thought to be a cause of insulin secretion during the 
cephalic phase of nutrient ingestion.  Ahren and Holst (3), however, found contraindicating 
results when circulating levels of GIP and GLP-1 failed to increase during the initial 10-
minute preabsorptive period after meal ingestion.  The study suggested that GIP is 
responsible for the insulin response at 15 minutes post meal ingestion via neural mediation.  
GIP and GLP-1 help insulin secretion further by aiding in decreasing β-cell apoptosis, and 
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enhancing β-cell insulin gene transcription, insulin biosynthesis, and β-cell proliferation 
(23, 81) with GLP-1 additionally inhibiting glucagon secretion (68).  It is also important to 
note that a GLP-1 receptor agonist (exendin-4) has been detected to produce similar effects 
of GLP-1, specifically increasing insulin secretion and β-cell mass as well as peripheral 
insulin sensitivity (60).  The use of the agonist from the Gila monster may be a helpful 
substitute for GLP-1 as it has been shown to be active for up to 12 hours in vast contrast to 
the rapidly degrading GLP-1 hormone.  Additionally, preventing the breakdown of the gut 
hormones with the application of a DPP IV inhibitor has also been shown to preserve the 
insulinotropic effects of the incretins (21). 
 
Metabolic Effects of Insulin 
After the stimulation and release from the pancreas, insulin initiates its effects on 
metabolism with insulin receptors present on target tissues and in high concentrations on 
muscle, adipose, and liver tissue.  Insulin binds to a receptor on the target tissue initiating a 
series of events that result in the activation of phosphoinositide 3-kinase (PI 3-kinase).  It is 
the activation of PI 3-kinase that plays a large role in the metabolic effects of insulin (77) 
including glucose uptake (82), glycogen synthesis (14), decreased lipolysis (65), and 
protein synthesis (53).  In skeletal muscle and adipose tissue, the cascade of events that take 
place lead to the uptake of glucose via a facilitative glucose transporter called GLUT 4 by 
causing the glucose transporters located within the cellular storage to translocate to the cell 
membrane to allow for glucose uptake (15).  Additional effects from insulin include fat 
synthesis, amino acid uptake, and inhibition of muscle and liver glycogenolysis (28). 
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Insulin and Exercise 
Immediately after aerobic exercise, plasma glucose and insulin responses during an oral 
glucose tolerance test are higher, suggesting an impairment in insulin sensitivity (41).  
Within 10-16 hours, the relative insulin resistance is followed by improved insulin 
sensitivity and glucose tolerance lasting for a few days without additional exercise.  
Improvements in insulin sensitivity from endurance training were found by King et al (42) 
when using a hyperinsulinemic, euglycemic clamp procedure.  Higher glucose disposal in 
response to the same amount of insulin was observed in trained subjects compared to 
untrained subjects, indicating higher insulin sensitivity.  Improved insulin sensitivity was 
also seen when using a hyperglycemic clamp procedure, where the trained subjects had 
significantly higher glucose disposal rates, and with lower plasma insulin concentrations 
indicating improved insulin action (43).  Although trained individuals indicate higher 
insulin sensitivity compared to untrained individuals, the effect elicited is due to an exercise 
effect rather than a training effect (43).  When trained individuals underwent 14 days of 
inactivity, their insulin response was significantly higher than one day after exercise with 
no change in glucose disposal.  The effect of exercise on insulin sensitivity was also 
demonstrated in a middle-aged, moderately exercising population in which they 
participated in 5 days of exercise followed by 7 days of inactivity with glucose tolerance 
testing within the period of inactivity (41).  The significant increase in glucose tolerance 
lasted 3 days but was diminished by 5 days after exercise again demonstrating a short term 
effect of physical activity on increased insulin sensitivity rather than an effect from training. 
The benefit of physical activity on insulin sensitivity has lead to research with 
treating metabolic diseases.  Relative risk of Type 2 diabetes decreased markedly with 
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increasing levels of physical activity noted by increasing levels of energy expenditure with 
involvement in aerobic activities such as walking, stairs, and recreational sports (31).  
Specifically, for each 500 kcal increase in energy expenditure, the risk of non-insulin 
dependent diabetes mellitus (NIDDM) decreased by 6 percent with the most protective 
effect of physical activity being in persons at the highest risk for NIDDM.  Resistance 
exercise has also shown to benefit insulin action in both healthy adults and adults with 
NIDDM.  In healthy adults participating in a training program for 16 weeks including a 
variety of muscular strength and endurance training exercises at moderate to vigorous 
intensity, an increase in muscular strength is accompanied by an increase insulin sensitivity 
during the hyperinsulinemic-euglycemic clamp procedure (56). Similar results have also 
been shown after strength training for as little as 20 weeks (79).  An increase in insulin 
sensitivity with resistance exercise also occurs in Type 2 diabetic adults.  During a 
resistance training program of 4 to 6 weeks at 5 days per week using approximately the 
same moderate to vigorous strength and endurance exercises, an increase in glucose 
disposal rates during the hyperinsulinemic-euglycemic clamp procedure was significant 
(37).   
For aerobic exercise recommendations concerning intensity, research has indicated 
that both low and high intensity aerobic exercise elicit similar effects to increase insulin 
sensitivity (11).  A general guideline states that a minimum intensity of moderate exercise 
(55 percent of VO2max) at an average of 3 to 4 sessions per week for 40 minutes over 20 
weeks is enough to elicit increased insulin sensitivity (92). While an increase in insulin 
sensitivity may be similar across low to high exercise intensities, it is also indicated that the 
exercise effects on glucose tolerance tend to be more exaggerated as exercise intensity 
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increases (12).  Specifically, exercise intensity is a better predictor of increased insulin 
action rather than exercise volume but overall the effect of exercise on insulin secretion 
suggests important implications for treating and managing metabolic diseases. 
 
Exercise and Incretins’ Role on Insulin 
Oral glucose administration causes a higher insulin response compared to an intravenous 
glucose infusion (62, 78) suggesting an important role of the incretin hormones in helping 
to control insulin release. In addition, the attenuation of the insulin response to glucose after 
exercise is more pronounced when glucose is administered orally compared with 
intravenous administration.  These findings suggest that the blunted insulin response that 
appears one day after exercise could be accounted for by changes in concentrations of GIP 
and GLP-1 which would alter the stimulation of insulin release under certain conditions. 
The effects of exercise on the release of gut hormones as well as their relationship 
with insulin secretion after exercise has only been studied to a small extent.  The effects of 
exercise on gut hormones present contraindicating results on the pattern of secretions 
during and after bouts of physical activity.  Martins et al. found GLP-1 levels to be 
significantly increased during and after one hour of exercise (49) agreeing with data from 
O’Connor and colleagues whom detected increases in GLP-1 during and after a 120 minute 
running bout (64).  While some studies have reported results on GLP-1 release in response 
to exercise and training, much of the gut hormone research is focused on weight loss and 
satiety levels.  Adam and others found GLP-1 release to be stimulated in lean subjects with 
60 minutes of physical activity compared to rest and further studied the effects of activity 
on obese subjects observing that before weight loss GLP-1 levels were not different during 
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physical activity compared to rest.  After significant weight loss the subjects’ GLP-1 levels 
were increased with physical activity (2).  De Luis et al. found resting GLP-1 levels to 
decrease after weight loss induced by physical activity and hypocaloric diet (16).  Previous 
literature on GIP indicates results showing no significant changes in GIP levels during and 
after exercise (33, 36, 64). Although it is helpful to know the effects of exercise on the gut 
hormone release, it would be even more so to determine the cause of less insulin release 
after exercising.  An early study on GIP demonstrated lower levels of GIP after exercise 
compared to non-exercised individuals in response to glucose ingestion (9) hinting at the 
important effects related to insulin release with exercise.  Together, these ideas highlight 
the implications of gut hormones in modifying insulin release when Shuster and others 
found that in normal subjects with the same basal plasma glucose, insulin secretion, C-
peptide, and GIP were all significantly higher in response to oral glucose ingestion 
compared to intravenous infusion (78).  Using the few studies that give evidence to 
relationship between gut hormones and blunted insulin release following exercise, future 
research is needed to confirm the influence of GIP and GLP-1 on insulin. 
Further studies have hinted of the relationship between the increased glucose 
disposal with a modest increase in insulin resulting from GLP-1 specifically.  While these 
studies have not examined the influence of exercise, the effects appear to be possibly 
related.  While we know that GLP-1 causes an increase in insulin, we also know that GLP-1 
is broken down rapidly from GLP-1-(7-36) to its metabolite GLP-1-(9-36).  It is the 
differences in these two forms that could be related to the blunted insulin response with an 
increase in glucose disposal.  Meier et al. found that when the GLP-1-(9-36) amide was 
infused the effects were a higher glucose uptake independent of changes in insulin, 
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glucagon, or gastric emptying (51).  The effects are in contrast to the infusion of GLP-1-(7-
36) which displayed a significant increase in insulin concentration along with the increase 
in glucose disposal.  This study indicates that while intact GLP-1 acts in an insulinotropic 
manner, its metabolite acts as an insulinomimetic.  Although GLP-1-(7-36) is more 
powerful in its effects of increasing glucose disposal, its previously speculated inactive 
metabolite is now giving rise to indicate its own independent actions. 
While GLP-1 plays an important role in insulin sensitivity, we have to acknowledge 
additional mechanisms that may contribute to the exercise effect.  During exercise, there is 
an increase in catecholamine levels (i.e. epinephrine and norepinephrine) due to 
sympathetic nervous system activation.  Increases in catecholamine levels in turn stimulate 
lipolysis (8) which leads to an increase in plasma free fatty acid content and therefore 
intramyocellular triglyceride content (10) with both contributing to an increase in insulin 
resistance (seen immediately post exercise).  Insulin resistance can then be reversed when 
plasma free fatty acids are lowered.  Exercise-induced rises in free fatty acids have been 
shown to decrease about 40 percent 13-16 hours post exercise and down to 10 percent of 
exercise levels between 21 and 24 hours post exercise (48).  The ability of exercise to help 
decrease lipid-induced insulin resistance remains unclear however the increase in fatty acid 
oxidation (40) as well as the augmented storage of fatty acids as intramyocellular 
triglyceride (6, 74) are two possible reasons as to why exercise induces insulin sensitivity 
after 24 hours in relation to free fatty acids.  Finally, muscle glycogen concentrations are 
related to insulin sensitivity after exercise as exercise depletes muscle glycogen stores and 
also withholding dietary carbohydrate consumption after exercise shows an increase in 
insulin sensitivity the following day (63).   
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Summary and Future Directions 
While hormones are only a small component of regulating insulin secretion, understanding 
the different mechanisms for the release of insulin is important during different 
circumstances, such as during exercise, in obese individuals, and diseased populations.  If 
these pathways and regulators are known, we can begin to treat and manage metabolic 
diseases in a much more efficient manner.  The initial investigations and clinical trials of 
using DPP IV inhibitors and exendin-4 have indicated promising potential in treating 
impaired glucose homeostasis and insulin action with incretin-related drug therapy, 
however the long term effects of this therapy (in relation to cancer risk specifically) are 
unknown.  Not only will it be significant to understand the regulators of insulin itself, but 
also it is essential to comprehend the effects of different conditions on the release GIP and 
GLP-1.  If we can understand these effects, it would help us to further realize their 
implications with insulin and treating disease. 
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CHAPTER 2. THE BLUNTED INSULIN RELEASE AFTER 
EXERCISE AND THE RELATIONSHIP WITH GASTRIC 
INHIBITORY POLYPEPTIDE AND GLUCAGON-LIKE PEPTIDE-1 
 
Abstract 
Introduction: During exercise training, an increase in insulin sensitivity is accompanied by 
a decrease in plasma insulin concentrations during an oral glucose tolerance test (OGTT).  
The purpose of this study was to investigate the role incretin hormones play in the blunted 
insulin release after exercise.  Gastric inhibitory polypeptide (GIP) and Glucagon-like 
peptide (GLP-1) are incretin hormones that cause insulin release after glucose ingestion.  
We hypothesized that insulin, GLP-1, and GIP concentrations during an OGTT would be 
lower after exercise compared to after 7 days of inactivity.   
Methods: Nine healthy men (n = 5) and women (n = 4) currently engaged in endurance 
exercise (23 ± 2 y) underwent 5 d of exercise at ~75% VO2peak for 60 min.  An OGTT was 
performed immediately post-exercise (IPE),  one day after exercise (Day 1) and one week 
later (Day 7).  Subjects were inactive between Day 1 and Day 7 (no exercise exceeding 
intensity of activities of daily living).   
Results: No change in body mass or body composition occurred during the study period.  
Glucose area under the curve (mmol/L x min) was significantly lower (P < 0.05) on Day 1 
(160 ± 65) compared with IPE (233 ± 65) and was similar on Day 7 (186 ± 94).  Although 
insulin sensitivity, as calculated by insulin-glucose index (pmol/L · min x mmol/L · min x 
104), did not reach significance between Day 1 (569 ± 328) and Day 7 (1,023 ± 810), the 
plasma insulin response curve was significantly higher during the Day 7 OGTT compared 
with IPE (P < 0.05).  Similarly, plasma GIP concentrations during the Day 7 OGTT were 
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significantly higher than Day 1 (P < 0.05).  No differences occurred within GLP-1 areas or 
OGTT responses. 
Discussion: These data suggest that GIP and GLP-1 do not play significant roles in the 
blunted insulin release after exercise.  The mechanism for the blunted insulin response may 
be important for furthering treatment of Type 2 diabetes and should continue to be studied, 
perhaps by focusing on other factors from the gut that influence insulin secretion. 
 
Introduction 
Immediately after exercise, higher plasma glucose and insulin responses during a 75-g oral 
glucose tolerance test suggest impairment in insulin sensitivity (14).  Within 10-16 h, the 
relative insulin resistance is followed by improved insulin sensitivity and glucose tolerance.  
This improved insulin action appears to last for three, but not 5 days (14). 
 Although the mechanism for a lower insulin secretion in response to glucose after 
exercise is unclear, there are factors in addition to glucose that stimulate the release of 
insulin from the pancreas.  Increases in plasma amino acid concentrations, fat ingestion, and 
the release of gut hormones all stimulate insulin release (15, 27, 28).  Two gut hormones 
that elicit the incretin effect are glucagon-like peptide-1 (GLP-1) and gastric inhibitory 
polypeptide (also referred to as glucose-dependent insulinotropic hormone, or GIP).   
The importance of gut hormones in modifying insulin release became clear after it 
was noted that oral glucose administration causes a higher insulin response compared to an 
intravenous glucose infusion (18, 23).  Shuster and others (23) found that in normal subjects 
with the same basal plasma glucose, insulin secretion, C-peptide, and GIP were all 
significantly higher in response to oral glucose ingestion (cephalic response) compared to 
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intravenous infusion.  The lower insulin response is also more pronounced with oral 
glucose administration. 
The insulin responses to glucose, arginine, and fat ingestion are all blunted in 
endurance trained people (15).  Although the plasma insulin concentrations continued to 
rise when intake of fat is combined with glucose and amino acid infusion, and fat ingestion, 
the plasma concentration of GIP decreased suggests other factors are regulating the release 
of insulin. Perhaps other gut hormones such as GLP-1 are responsible for the reduced 
release of insulin in endurance trained people. 
 Few studies have investigated the gut hormones response to exercise.  An early 
study on GIP demonstrated lower levels of GIP after exercise compared to non-exercised 
individuals in response to glucose ingestion (3).  O’Connor and colleagues (19) detected 
increases in GLP-1 during and after a 120 minute running bout.  De Luis et al. (6) found 
resting GLP-1 levels to decrease after weight loss induced by physical activity and 
hypocaloric diet.  Previous literature on GIP indicates that significant changes in GIP levels 
do not occur during and after exercise (10, 11, 19).  Because of the limited research on 
GLP-1 and GIP related to exercise training and the blunted response of insulin, it was the 
purpose of this study to investigate the role of GIP and GLP-1 in the blunted insulin 
response after exercise.  We hypothesized that plasma gut hormone concentrations will be 
significantly higher seven days after cessation of exercise compared to immediately after 
exercise and one day after exercise similar to the trend of insulin concentrations. 
 
 
 
 30
Materials and Methods 
Subjects. Participants recruited for this study were 10 healthy, trained 18-27 y old adults.  
The data of one female subject was excluded from analysis due to an anomalous decrease in 
plasma glucose after ingestion of 75-g glucose resulting in 5 males and 4 females for final 
data presentation.  All subjects recruited into the study were engaged in endurance exercise 
at a minimum level of 30 min continuous, 3 times per week, and an intensity of 60% of 
their maximum heart rate reserve.  All subjects gave written informed consent as approved 
by the Iowa State Human Subjects Committee before starting the study.  Subjects provided 
a medical history and underwent body composition analysis and a graded exercise test. 
Subject characteristics are given in Table 2. 
 
 Table 2. Subject Characteristics. 
    
 Exercising      Inactive 
Age, y 
Height, cm 
   Women 
   Men 
Body Mass, kg 
   Women 
Men 
Body Mass Index, kg/m2 
Body Fat %, Skinfolds 
    Women 
    Men 
Body Fat %, Hydrostatic 
    Women 
    Men 
VO2peak 
   L/min 
     Women 
     Men 
   ml/kg/min 
     Women 
     Men 
     23 ± 2   
173.4 ± 9.5 
166.2 ± 3.2 
180.7 ± 7.7 
  67.0 ± 12.8      67.1 ± 12.7 
  59.3 ± 5.6        59.5 ± 5.3 
  74.6 ± 13.8      74.6 ± 13.9 
  22.1 ± 2.5 
  14.4 ± 5.3        14.5 ± 5.5 
  18.5 ± 2.5 
  10.2 ± 3.9  
   
  19.9 ± 3.9 
  14.9 ± 5.0 
 
  3.58 ± 0.7 
  3.09 ± 0.2 
  4.08 ± 0.7 
  53.5 ± 2.4 
  52.2 ± 2.3 
  54.8 ± 1.9 
 Values are means ± SD; n = 4 women and 5 men.VO2peak, peak O2 uptake. 
 31
Experimental Protocol.  Subjects performed 60 min of continuous exercise at a work rate 
calculated to elicit 75% of VO2peak for five consecutive d.  Two subjects exercised on the 
treadmill and eight subjects exercised on the cycle ergometer.  Heart rate and oxygen 
uptake (VO2) were measured for 5 min every 20 min interval to determine exercise 
intensity (Max II Metabolic Systems, Physiodyne Metabolic Cart).  Immediately post 
exercise (IPE) on the fifth d, subjects underwent an OGTT and blood sampling as well as 
on d 1 and 7 after the last exercise d.  During this time subjects did not undergo vigorous 
physical activity.  The experimental protocol is detailed in Figure 1.  
 
 
Figure 1. Experimental protocol. Body Comp, body composition via hydrostatic weighing and 
skinfolds; OGTT, oral glucose tolerance test; IPE, immediately post-exercise. 
 
Body Composition. Body composition was measured with hydrostatic weighing and 
skinfold calipers with skinfold assessment done both before and after 7 d of physical 
inactivity (Lange Skinfold Calipers, Beta Technology Inc., Cambridge, MA).  For 
hydrostatic weighing, subjects performed a minimum of four trials and the mean of the two 
highest trials was used for the underwater weight.  Residual lung volume was estimated as 
the proportion of vital capacity (0.24 for men, 0.28 for women) after measurement with a 
spirometer (30).  Body density for skinfold measurements was calculated for males and 
Exercising Inactive 
VO2peak 
Body Comp 
Baseline 
60 Minute Continuous Exercise @ 75% 
VO2peak 
Day 1 
OGTT 
Day 3 Day 1 Day 2 Day  4 Day 5 
 
OGTT OGTT 
IPE 
  
Day 7 
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females using the Jackson and Pollock equations (12, 13).  Body fat percentage was 
calculated using the equation of Siri (4.95/density-4.50 x 100) (24).   
 
Estimation of VO2peak.  VO2peak was estimated during a maximal graded exercise test on 
an electromagnetically braked cycle ergometer or a treadmill.  Tests on the ergometer 
consisted of 2 min stages beginning at 50 W with an increase in power output of 50 w for 
each stage.  Tests on the treadmill started at 5 mph for females and 6 mph for males and 
consisted of 2 min stages with an increase in workload of 1 mph after each stage.  Tests 
were terminated when the subjects reached maximal fatigue. Expired gases were collected 
during each min of exercise.   
 
OGTT and Blood Analyses. Subjects reported to the lab after an overnight fast and blood 
samples were taken before, and 30, 60, 90, and 120 min after ingestion of 75 g of glucose 
dissolved in 300 mL of water.  Blood samples were collected without stasis into EDTA 
tubes and kept on ice before centrifugation and storage (-80 C) until analysis.  Blood 
samples for GIP and GLP-1 analysis were immediately combined with 200 KIU aprotinin 
per 1 mL whole blood.  Plasma glucose concentrations were measured by the glucose 
oxidase method (YSI 2300 GL, Yellow Springs Instruments, Yellow Springs, OH). Plasma 
insulin concentrations were analyzed by radioimmunoassay (RIA) according to previously 
described methods (8, 31); porcine insulin was used as standards.  The intra-assay and inter-
assay coefficient of variation (CV) for the insulin assay were 8% and 12%, respectively. 
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GIP.  Plasma GIP concentrations were measured by RIA technique using rabbit anti-human 
GIP antibody (Phoenix Pharmaceuticals), 125I-labeled human GIP, and human GIP 
standards (American Peptide).  Radioiodination of human GIP was done using a modified 
Chloramine-T method (4).  The iodination mixture was applied to a G-50 Sephadex column 
at 4˚C and eluted with elution buffer (0.1 M acetic acid, 0.5 M NaCl, 0.1% BSA, 3 mM 
NaN3, pH 5.0) while 1 ml fractions were collected at the rate of 6 ml/hr.  Assay was 
performed in polypropylene tubes with incubations at 4˚C using a phosphate dilution buffer 
containing BSA, Na2EDTA, and NaN3 (pH 7.4).  The dilution buffer containing 500 KIU 
aprotinin/ml was used for dilution of GIP antibody (final dilution 1:10,000), 125I-GIP 
(15,000 cpm/0.1 ml), and GIP standards containing 100 to 12,800 pg/ml.  Standards or 
plasma samples (0.1 ml) were added to the tubes followed by the first antibody (rabbit anti-
human GIP). After 24 hr incubation, 0.1 ml of 125I-GIP was added to each tube followed by 
24 hr incubation again.  Normal rabbit plasma (0.1 ml; 1:80) and second antibody (0.1 ml; 
goat antiserum vs rabbit IgG; 1:40) was added followed by 10 minute incubation at room 
temperature.  Finally 0.1 ml of human serum was added to each standard and 1 ml of 
polyethylene glycol solution was added to each tube before centrifugation at 3,000 rpm for 
30 min at 4˚ C.  The supernatant was aspirated before the tubes were counted with a gamma 
counter.  The interassay and intraassay CV for GIP RIA was 3% and 7%, respectively. 
 
GLP-1.  Plasma samples for GLP-1 were extracted with ethanol before radioimmunoassay 
procedure using mouse anti-human GLP-1 (Bachem), 125I-labeled GLP-1, and human GLP-
1 (American Peptide).  Radioiodination of human GLP-1 was done similarly to the methods 
described above for GIP.  Assays were performed in glass tubes with incubations at 4˚C 
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using a phosphate dilution buffer containing BSA, Na2EDTA, and NaN3 (pH 7.4).  Dilution 
buffer containing 500 KIU aprotinin/ml was used for dilutions of 125I-GLP-1 (~20,000 
cpm/0.1 ml) and GLP-1 standards containing 3.9 to 500 pmol/L.  Standards or samples (0.1 
ml) were added to the tubes following reconstitution in assay buffer and followed by 
addition of the first antibody. After 24 hr incubation, 0.1 ml of 125I-GLP-1 was added to 
each tube followed by 24 hr incubation again.  Normal rabbit plasma (0.1 ml; 1:80) and 
second antibody (0.1 ml; goat antiserum vs rabbit IgG; 1:20) was added followed by 20 
minute incubation at room temperature.  Finally 0.1 ml of bovine serum and 1 ml of 
polyethylene glycol solution was added to each tube before centrifugation at 3,000 rpm for 
30 min at 4˚ C.  The supernatant was aspirated before the tubes were counted with a gamma 
counter. 
 
Dietary control. Diet was controlled by instructing the subjects to consume at least 200 g of 
carbohydrates total 7 d before the OGTT and during the 7 d of physical inactivity.  Subjects 
recorded a 3-d diet record for the 3 d before the first OGTT and were instructed to eat 
exactly the same diet for the 3 d before the d 7 OGTT therefore being the same days of the 
week before each test.  The diet was analyzed using the United States Department of 
Agriculture (USDA) Center for Nutrition Policy and Promotion online computer program. 
 
Statistical Analysis. Glucose, insulin, GIP, and GLP-1 areas during the OGTTs were 
calculated by using a trapezoidal model that summates the area above baseline.  To estimate 
insulin sensitivity, the product of insulin and glucose curves was calculated (IG index). The 
IG index is the product of the areas under the glucose and insulin curves and is inversely 
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related to insulin sensitivity (16).  The data was analyzed with commercially available 
software (SPSS, Chicago, IL).  Plasma glucose, insulin, GIP, and GLP-1 responses during 
the OGTTs were analyzed with two-way analysis of variance for repeated-measures 
designs. Post-hoc tests were performed where appropriate using a multiple comparisons test 
with a Bonferroni adjustment.  Effect sizes (ES) were calculated for areas above baseline 
where appropriate using Cohen’s d equation and effect sizes for the two-way ANOVA 
OGTT response curves were calculated using a partial eta squared (ηp2) equation. 
Incremental glucose, insulin, GIP, and GLP-1 areas and IG index were analyzed with one-
way analysis of variance. 
 
Results 
Exercise, diet, and body composition. During the 5 days of exercise, subjects exercised for 
60 min at an exercise intensity that elicited a VO2 of 39.8 ± 3.4 ml/kg/min or 72 ± 5% of 
estimated VO2peak.  Although the subjects were not given a controlled diet, the dietary 
intake reported by the subjects maintained a minimum amount of total carbohydrate (200 g) 
intake while subjects also reported that their 3 day diet before the first OGTT was 
replicated before the last OGTT (Table 3).  Seven days of inactivity did not result in any 
significant changes in body composition (Table 2). 
 
Table 3. The dietary intake before the IPE and Day 7 oral glucose tolerance tests. 
 
                                   kcal             Carbohydrate, g          Fat, g                  Protein, g 
Day 1 
Day 2 
Day 3 
2,634 ± 522 
2,654 ± 829 
2,609 ± 866 
341 ± 85 
342 ± 72 
326 ± 66 
84 ± 42 
88 ± 40 
94 ± 33 
113 ± 52 
105 ± 43 
118 ± 70 
Values are means ± SD; n = 9 subjects. IPE, immediately post exercise. 
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Glucose Tolerance. The plasma glucose response tended to be elevated during the OGTT’s 
performed IPE and day 7 compared with day 1 although not significantly (P > 0.05; Fig. 2). 
The largest difference occurred when comparing IPE and day 1 (P = 0.09; ES = 0.33). The 
incremental area above fasting plasma glucose concentration was calculated (Fig. 3) and the 
fasting glucose area under the curve was significantly elevated IPE (233 ± 65 mmol/L x 
min) compared to Day 1 (160 ± 65 mmol/L x min; P ≤ 0.05; ES = 1.13).  No significant 
change in the glucose area was observed from day 1 to day 7 (186 ± 94 mmol/L x min; ES 
= 0.59) nor was there a difference between IPE and day 7 (ES = 0.32).  
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Figure 2. Plasma glucose response during 75 g oral glucose tolerance test. Values are  
means ± SD of 9 subjects. IPE, immediately post exercise.  
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Figure 3. Area above baseline under plasma glucose response curve during 75 g oral glucose 
tolerance test.  Values are means ± SD of 9 subjects. * Significantly different from IPE, P ≤ 0.05. 
 
 
Insulin Response.  The insulin response to oral glucose was significantly higher on Day 7 
compared to immediately after exercise (P < 0.05; Fig. 4).  No difference occurred between 
IPE and Day 1 and although the insulin response was not statistically significantly different 
between Day 1 and Day 7, there was a tendency for Day 7 to be greater than Day 1 also (P 
= 0.08; ES = 0.53).  The incremental insulin area on Day 7 (59,041 ± 25,778 pmol/L x min) 
was significantly higher (P < 0.05) compared with immediately post exercise (35,395 ± 
12,445 pmol/L x min; ES = 1.10) and Day 1 (41,568 ± 13,505 pmol/L x min; ES = 0.96).  
After seven days of inactivity, the insulin area was 41% higher compared with that on Day 
1 (Fig. 5).  No difference occurred between IPE and Day 1 (ES = 0.24). 
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Figure 4. Plasma insulin response during 75 g oral glucose tolerance test. Values are  
means ± SD of 9 subjects. IPE, immediately post exercise. * Significantly different from 
IPE, P < 0.05; + Day 7 time point significantly higher than Day 1, P < 0.01; ‡ Day 7 time  
point significantly higher than IPE, P < 0.01. 
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Figure 5. Area above baseline under plasma insulin repsonse curve during 75 g oral  
glucose tolerance test. Values are means ± SD of 9 subjects. IPE, immediately postexercise. 
* Significantly different from Day 7, P < 0.05. 
+ 
‡ 
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Insulin Sensitivity.  The product of the incremental glucose and insulin areas (IG index) was 
calculated (Fig. 6) to assess the effect of exercise on insulin sensitivity.  The IG index 
(mmol/L · min × pmol/L · min × 104) was elevated (P = 0.061) on Day 7 (1,023 ± 810) 
compared to Day 1 (569 ± 328; ES = 0.81) although not significant.  The IG index 
immediately after exercise (745 ± 397) was not significantly different than Day 1 (ES = 
0.69) or Day 7 (ES = 0.45). 
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Figure 6. Insulin-glucose (IG) index [product of insulin and glucose areas (pmol/L · min x 
mmol/L · min x 104) during 75 g oral glucose tolerance test.  Values are means ± SD of 9 
subjects. IPE, immediately postexercise. 
 
 
Plasma GIP.  Although the plasma GIP response to the oral glucose tended to be higher on 
Day 7 compared to IPE (similar to the insulin response), the plasma GIP response was only 
significantly different on Day 7 compared with Day 1 (P < 0.05; ES = 0.60; Fig 7).  The 
plasma GIP area above baseline was not different (Fig. 8) between IPE (3311 ± 1141 
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pmol/L x min), Day 1 (3626 ± 1707 pmol/L x min), or Day 7 (3483 ± 1963 pmol/L x min).  
Effect sizes were considered small for all 3 comparisons (IPE vs Day 1 ES = 0.22; IPE vs 
Day 7 ES = 0.11; Day 1 vs Day 7 ES = 0.08). 
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Figure 7. Plasma GIP response during 75 g oral glucose tolerance test.  Values are means ± SD 
of 9 subjects. IPE, immediately post exercise. * Significantly different from Day 7, P < 0.05. 
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Figure 8. Area above baseline under plasma GIP repsonse curve during 75 g oral glucose 
tolerance test.  Values are means ± SD of 9 subjects. IPE, immediately postexercise. 
 
Plasma GLP-1.  There was no main effect of day for the plasma GLP-1 responses during 
the oral glucose tolerance tests (P > 0.05; ES = 0.03; Fig 9).  The plasma GLP-1 area above 
baseline was not different (Fig. 10) between IPE (2287 ± 2034 pmol/L x min), Day 1 (2704 
± 3201 pmol/L x min), or Day 7 (1040 ± 1199 pmol/L x min).  Effect sizes were medium 
for IPE vs Day 7 (ES = 0.74) and Day 1 vs Day 7 (ES = 0.69) and small for comparison 
between IPE and Day 1(ES = 0.16). 
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Figure 9. Plasma GLP-1 response during 75 g oral glucose tolerance test.  Values are  
means ± SD of 9 subjects. IPE, immediately post exercise. 
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Figure 10. Area above baseline under plasma GLP-1 repsonse curve during 75 g oral glucose 
tolerance test.  Values are means ± SD of 9 subjects. IPE, immediately postexercise. 
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Gender Responses:  No significant differences occurred between males and females within 
the areas under the curves for any of the variables measured.  Within the responses to the 
OGTT’s, the insulin concentrations were significantly higher for females on Day 7 (P < 
0.05); the GIP responses were significantly higher for males IPE (P < 0.05); and the GLP-1 
responses were significantly higher for females IPE, Day 1, and Day 7 (P < 0.05). 
 
Discussion 
The purpose of this study was to examine the possible relationship that GIP and GLP-1 has 
on insulin release immediately after physical activity and after a period of inactivity.  In 
order to study this relationship, the subjects went through 5 days of exercise followed by 7 
days of inactivity aimed to elicit changes in insulin sensitivity and therefore insulin release.  
The results of the oral glucose tolerance tests indicated that the subjects tended to have 
decreased insulin sensitivity after 7 days of inactivity as shown by the IG index. Although 
the IG index on Day 7 compared to Day 1 was not significant, the insulin area under the 
curve on Day 7 was significantly higher than both IPE and Day 1 supporting a decrease in 
insulin sensitivity during inactivity characterized by higher insulin release (as well as a 
large effect size comparing the IG index between Day 1 and Day 7).  The glucose response 
however, did not elicit a significant increase from Day 1 to Day 7 as would be expected.  
The decreased insulin sensitivity in young, healthy, and endurance-trained subjects during a 
short period of inactivity agrees with several previous studies. Arciero et al. (2) observed 
significant increases in the area under the glucose and insulin curves after 7-10 days of 
inactivity relatively within the same target population, although much larger changes 
occurred compared to the current study.   
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One reason glucose and insulin responses to inactivity were not as exaggerated 
compared to other studies could be explained by dietary intake.  The subjects in the current 
study recorded a dietary intake of 1,000 kcal/day less than the study by Arciero.  A higher 
caloric intake combined with inactivity has been shown to contribute to an increase in 
insulin resistance in young, healthy subjects (9).  Also lower dietary fat intake could 
support the moderate change in insulin sensitivity.  The subjects in our study reported a 
dietary fat intake of less than 30 percent of total energy intake.  Stettler et al. (26) compared 
a high fat diet (~45 percent of total energy intake) versus a high carbohydrate diet on 
insulin sensitivity illustrating a decrease in glucose tolerance with the high fat diet.  
Moderate calories combined with low fat intake could be contributors to the moderate 
changes in insulin sensitivity during 7 days of inactivity in this population. 
Gender differences could also explain some of the variability within the analysis.  
The insulin response to glucose after 7 days of inactivity was significantly higher in females 
than males.  Previous literature on insulin concentrations in response to glucose is 
contraindicating with several studies indicating no difference between genders (1, 5).  The 
response of GLP-1 during all the OGTT’s were significantly higher for females also which 
agrees with previous research (1) in response to a standard breakfast meal while other 
research indicates males having higher GLP-1 responses (5). 
 The plasma insulin concentrations were higher for Day 7 compared to IPE and Day 
1 and were significantly different compared to IPE.  This trend coincided with the plasma 
GIP concentrations during the oral glucose tolerance test as the plasma GIP curve for Day 7 
was the highest, while only significantly higher than Day 1.  These data demonstrate that as 
insulin sensitivity decreases over a week of inactivity, GIP may be a factor contributing to 
 45
the changes in insulin release according to the main effect of the different days of the tests.  
Previous work by Hansen et al. (9) demonstrated a large increase in GIP concentrations 
after a period of inactivity combined with a high-caloric diet and steroid treatment.  The 
incretin effect was also calculated using the difference between β-cell secretory responses 
for insulin, C-peptide, or insulin secretion rate between stimulation with the oral glucose 
tolerance test and the isoglycemic intravenous glucose infusion.  The relative incretin effect 
for all three comparisons was significantly worse after the 12 days of treatment.  Although 
this evidence illustrates an effect that exercise may have on GIP to influence changes on 
insulin release, a closer look at the current data may highlight that the role of GIP is not so 
significant.  When comparing the shapes of the insulin and GIP curves during the OGTT’s, 
it is evident that the rise and fall of concentrations are not temporally related.  The insulin 
curve has a very exaggerated increase from 0 to 30 minutes followed by a similar 
exaggerated decrease in concentrations starting at 30 to 60 minutes.  GIP similarly increases 
from 0 to 30 minutes however after 30 minutes illustrates a relatively small increase or 
plateau.  The lack of similarity between insulin and GIP release patterns during the OGTT’s 
indicates that in fact, GIP is not the significant contributor to insulin release changes with 
exercise even with a similar main effect for day. 
 The idea that GIP may only be a small or insignificant component of the cause of 
the insulin release after exercise is supported by other studies.  Blom (3) previously 
compared insulin and GIP release during exercise and for 6 hours after that exercise with 
glucose given every 2 hours.  The results compared the exercise group to a non-exercise 
group and showed no difference in insulin release between the groups.  Interestingly, the 
GIP was significantly higher in the plasma in the non-exercise group.  This significant 
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change in GIP without a corresponding change in plasma insulin concentrations indicates 
GIP was not the primary factor in causing insulin release.  A later study by King et al. (15) 
examining the insulin secretory capacity in trained versus untrained men also investigated 
plasma GIP and found that during a hyperglycemic clamp with arginine infusion and fat 
meal, insulin levels continued to rise throughout the 135 minutes of the modified 
hyperglycemic clamp.  Plasma GIP, however actually decreased during the modified clamp 
procedure.  Although the glucose was infused intravenously (perhaps explaining some of 
the decreases in GIP different to our study in which glucose was ingested orally), this data 
still illustrates a further aspect to significantly control insulin release with exercise, such as 
GLP-1. 
 There are several possible reasons for the changing GIP concentrations with 
inactivity.  The lower plasma GIP released after exercise could be related the activity of α-
adrenergic receptors with exercise.  Salera et al. found that after infusion of epinephrine 
increased the activity of α-2 adrenergic receptors, this increased and significantly reduced 
the GIP response (22).  Somatostatin also inhibits GIP release and is affected by exercise, 
and somatostatin concentrations are elevated after exercise (20). 
 It is evident that GLP-1 is also not responsible for the changes in insulin release 
with exercise.  There were no significant differences between the different days for the 
GLP-1 curves or areas.  Although the plasma GLP-1 concentrations tended to increase from 
baseline to 30 minutes, the changes were very small changes with subsequent plateaus 
unlike the insulin responses.  The minimal increases in GLP-1 concentrations in response to 
75-g of oral glucose intake is consistent with previous literature.  Steiner et al. found 
increases in GLP-1 to be a little as 2.7 pmol/L in response to a glucose load in healthy 
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subjects (25).  Others have observed increases of as much as 20 to 40 pmol/L of plasma 
GLP-1 within the first 30 minutes of OGTT’s (7, 17, 29).  More importantly, in a similar 
intervention study by Hansen et al. the area under the curve for GLP-1 was not significantly 
different before and after a period of physical inactivity (9).  Hansen et al did find, 
however, that the mean GLP-1 concentration at baseline was significantly higher after 12 
days of inactivity combined with a high-caloric diet and steroid treatment. 
The large range in basal and peak levels of GLP-1 within the literature illustrates the 
difficulty in measuring GLP-1.  In the current study there was also very large variability in 
concentrations.  The rapid rate of GLP-1 degradation in the blood could be one possible 
reason for these differences.  Another possible limitation to our study could be the 
conservative amount of aprotinin added to the blood samples to prevent incretin 
degradation.  Limited aprotinin along with the absence of specific DPP IV inhibitors could 
combine to magnify the variation in GLP-1 concentrations.  Other limitations within this 
study include a small sample size and subjects’ accountability concerning inactivity and 
diet replication. 
  
Conclusions 
 
The responses of GIP and GLP-1 in this study indicate these incretins are not responsible 
for the reduced insulin response after exercise.  The high variability with GLP-1 values 
specifically, sheds light on the need for further research on this peptide in general and in 
relation to exercise-related insulin changes.  More importantly, because the blunted insulin 
release after exercise has been shown to be more exaggerated with an oral glucose load, 
other factors from the gut should be studied to determine the cause of this change with 
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insulin.  Since cholecystokinin (CCK) has been linked to changes in insulin sensitivity, it 
may be one candidate (21).  The value of determining the causes of the blunted insulin 
release after exercise may be significant in understanding the mechanisms behind insulin 
resistance and Type 2 diabetes and the evidence indicating the connection between the 
incretins and insulin sensitivity and the reduced incretin effect in diabetic patients further 
illustrates the importance of studying this issue.  Future studies using incretin infusion or 
tracer techniques could be focused on to determine the mechanism(s) for the exercise effect 
of insulin sensitivity as well as studies investigating the role of other insulin factors from 
the gut. 
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CHAPTER 3. GENERAL CONCLUSIONS 
 
 
Insulin resistance is currently a huge problem for a large part of the population in our 
country, especially for the clinically obese.  Becoming glucose intolerant is caused by 
factors including physical inactivity, high fat body composition, and poor diet to name a 
few.  Pharmacology is becoming an important method of treatment; however it is also very 
important to utilize exercise as an effective method for both prevention and treatment of 
insulin resistance.   As indicated by numerous studies, exercise can effectively benefit 
insulin sensitivity through aerobic endurance and resistance activities; however these 
benefits are diminished if the exercise is not maintained.   
 The effect of exercise on insulin is associated with a decrease in plasma insulin 
concentrations with no change or an increase in glucose disposal in response to an oral 
glucose load.  The reasons for this blunted insulin release after exercise however is 
unknown.  This study investigated two of the factors that cause insulin release to examine 
this mechanism.  The incretin GIP coincided with insulin levels in response to exercise and 
a period of inactivity within the main effect for day only.  The specific pattern of GIP 
release compared to insulin however, indicates that GIP probably does not play a role in the 
blunted insulin response after exercise.  The response of GIP makes sense when examining 
the factors that influence GIP release, such as somatostatin and the adrenergic receptors, 
and connecting the idea that they too could be affected by exercise. The GLP-1 data also 
showed no similarities with insulin data.  In general, neither of these hormones indicates a 
significant contribution to the insulin mechanism with exercise.  
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There remains a need for future research within this topic as the literature also 
supports that GIP and GLP-1 are not the only factors to contribute to the blunted insulin 
mechanism with exercise.  The idea that the exercise induced insulin changes are more 
pronounced with an oral glucose load rather than an intraveneous load still point to factors 
from the gut.  One factor that needs to be investigated further would be CCK.  On the other 
hand, knowing there are some similarities with GIP and the highly inconsistent data on 
GLP-1 indicates that it may still be important to further study these incretins to help 
confirm these ideas.  Using a tracer or infusion techniques may help to investigate the issue 
further.  Future research on this mechanism is important because it could help to treat 
diabetic patients with a better understanding of the physiological level of the disease.  
Along with furthering the literature on this topic, it is also important as an exercise 
physiologist to stress the take-home message as using exercise as an effective way to 
maintain a healthy and disease-free lifestyle. 
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APPENDIX.  RAW DATA 
 
Table 4. Subject characteristics. 
     Body Composition %Fat   
Subject 
Age 
yr 
Height 
cm 
Body 
Mass kg BMI UWW 
PreTest 
Skinfolds 
PostTest 
Skinfolds 
VO2peak 
L/min 
VO2peak
ml/kg/min 
801 23 189 73.1 24.1 11.9 9.0 8.7 4.70 55.1 
802 27 184 62.2 18.4 22.5 9.0 9.1 3.38 54.4 
803 23 185.5 92.7 26.9 16.4 16.7 17.0 4.86 52.4 
804 22 173 70.2 23.5 9.5 6.2 6.4 3.82 54.4 
805 22 172 62.5 21.1 14.4 10.4 10.3 3.62 57.8 
Male 
Mean 23.4 180.7 72.14 22.8 14.9 10.2 10.3 4.08 54.8 
806 25 166.5 66 23.8 21.4 21.5 20.9 3.28 49.6 
807 23 169.5 59.2 20.6 21.2 15.3 14.6 3.05 51.3 
808 24 162 53.7 20.5 13.6 16.6 17.5 2.99 55.9 
809 21 168.9 63.7 22.3 19.4 19.5 20.5 3.32 52.3 
810 21 164 54 20.1 24.0 19.6 20.5 2.81 52.1 
Female 
Mean 22.8 166.2 59.3 21.5 19.9 18.5 18.8 3.09 52.2 
Total 
Mean 23.1 173.4 65.7 22.1 17.4 14.4 14.5 3.58 53.5 
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Table 5. Plasma glucose concentrations during the oral glucose tolerance tests for each subject. 
 Time 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 0 4.3 4.2 4.5 4.8 4.5 5.4 4.7 4.2 4.7 4.0 4.4 
 30 7.2 7.9 8.4 9.0 8.5 4.7 7.6 6.1 7.2 6.7 7.6 
 60 8.1 4.9 8.4 7.9 7.7 2.9 8.2 6.0 6.2 6.3 7.1 
 90 6.7 3.9 6.3 6.0 6.9 3.7 6.9 5.1 5.8 5.9 5.9 
 120 5.4 3.9 4.0 4.2 4.8 4.3 7.4 5.5 5.6 6.0 5.2 
Day 1 0 4.6 4.7 4.9 5.0 5.0 4.6 4.7 4.5 4.6 4.7 4.7 
 30 6.9 7.5 9.3 9.4 9.0 6.0 6.1 6.9 7.3 5.9 7.6 
 60 7.3 6.2 7.5 8.2 6.6 4.4 7.7 5.1 7.1 4.7 6.7 
 90 6.5 4.3 3.6 5.3 5.6 4.0 5.5 4.1 5.4 4.5 5.0 
 120 5.3 4.1 2.9 5.0 5.2 4.3 4.5 3.5 5.5 4.4 4.5 
Day 7 0 4.8 4.7 5.3 4.7 5.2 4.6 4.7 4.5 4.6 4.9 4.8 
 30 6.6 8.0 7.3 9.5 9.4 6.0 7.8 5.8 7.6 6.8 7.6 
 60 6.5 7.4 8.0 9.3 8.2 4.5 8.6 4.1 3.4 6.8 6.9 
 90 6.8 5.9 4.3 6.1 7.2 5.2 7.0 3.5 4.9 5.6 5.7 
 120 5.7 4.0 4.0 3.7 4.8 4.6 5.2 3.8 5.5 5.4 4.7 
Units: mmol/L 
 
 
 
 
 
Table 6. Glucose area above baseline for each subject. 
 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 294 132 281 246 289 0 293 158 168 241 233 
Day 1 220 128 200 236 184 37 155 89 194 36 160 
Day 7 182 209 132 314 273 54 290 34 99 144 186 
Units: mmol/L x min 
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Table 7. Plasma insulin concentrations during the oral glucose tolerance tests for each subject. 
Time 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 0 7.8 19.3 33.9 74.2 7.4 163 69.8 33.5 121 15.3 42.5 
 
30 39.4 316 163 488 230 473 216.1 284 549 426 302 
 
60 205 308 265 378 266 309 369.7 549 641 396 375 
 
90 107 210 98.5 284 220 305 296.9 315 287 315 237 
 
120 15.8 129 21.2 118 83.5 296 593.7 349 557 310 242 
Day 1 0 9.25 24.6 19.6 58.8 17.8 59.0 51.3 26.2 97.3 33.2 37.6 
 
30 117 116 426 707 528 675 217 577 544 579 423 
 
60 338 314 340 929 211 519 450 428 350 433 421 
 
90 120 147 40.3 596 237 363 454 270 376 428 296 
 120 99.9 121 14.2 273 154 451 427 193 317 313 213 
Day 7 0 16.8 16.1 20.4 62.1 38.1 256 46.0 61.0 42.8 52.6 39.5 
 30 235 285 155 628 217 1043 266 934 453 776 438.8 
 60 192 420 364 489 364 266 583 1080 297 798 509.6 
 90 283 368 220 451 602 787 1236 561 340 577 515.4 
 120 211 284 122 329 300 417 382 495 362 457 326.9 
Units: pmol/L 
 
    
 
 
 
Table 8. Insulin area above baseline for each subject. 
 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 20360 32083 17013 31059 47569 24179 35957 48098 50281 47348 36641 
Day 1 24363 22685 27476 54911 35917 58702 46650 48055 40593 56329 39664 
Day 7 29878 36982 30025 57713 68124 50448 89371 101034 41951 84887 59996 
Units: pmol/L x min x 103 
 
 
 
 
 
Table 9. Insulin-Glucose index  for each subject. 
 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 599 424 478 764 1374 0 1065 761 845 1140 828 
Day 1 535 290 549 1298 660 219 724 429 785 203 608 
Day 7 542 774 396 1809 1860 272 2594 343 414 1222 1106 
Units: pmol/L · min x mmol/L · min x 104 
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Table 10. Plasma GIP concentrations during the oral glucose tolerance tests for each subject. 
 Time 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 0 29.0 24.9 26.6 29.3 30.8 - 14.4 19.6 14.4 19.4 23.15 
 
30 48.2 67.0 56.0 55.0 66.1 - 40.0 27.6 38.9 26.3 47.22 
 
60 49.2 55.1 57.1 44.8 88.9 - 36.6 43.3 32.4 32.3 48.85 
 
90 49.3 59.7 43.9 43.0 66.6 - 43.3 52.8 39.6 39.5 48.62 
 
120 44.9 68.7 32.1 46.0 40.4 - 25.4 48.6 42.8 30.8 42.20 
Day 1 0 23.7 32.4 34.2 25.4 31.8 - 7.9 18.3 20.2 14.0 23.09 
 
30 50.5 54.0 49.7 55.0 69.1 - 18.0 67.3 42.3 27.6 48.15 
 
60 54.1 56.6 56.6 59.8 59.0 - 34.3 69.2 34.4 23.3 49.70 
 
90 48.0 60.2 39.3 42.1 89.5 - 42.6 73.6 42.0 30.7 51.99 
 
120 49.1 62.7 28.9 58.0 62.6 - 39.2 69.8 32.2 28.9 47.92 
Day 7 0 29.0 31.3 31.0 36.8 42.9 - 12.0 19.0 23.7 13.9 26.63 
 
30 39.9 63.1 43.9 63.8 58.7 - 28.0 70.5 51.8 39.2 51.00 
 
60 52.6 56.1 45.5 60.4 62.2 - 37.0 66.7 23.7 32.2 48.49 
 90 46.6 69.8 43.7 51.1 79.7 - 41.6 94.8 48.8 28.8 56.12 
 120 53.7 65.3 46.5 48.2 71.4 - 36.0 102.7 48.0 32.9 56.08 
Units: pmol/L 
 
 
 
 
 
Table 11. GIP area above baseline for each subject. 
 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 2636 4846 3120 2335 5423 - 3235 3229 3109 1865 3311 
Day 1 3650 3440 1668 3671 5405 - 3516 7025 2466 1794 3626 
Day 7 2546 4311 1837 2696 3425 - 3296 8354 2345 2539 3483 
Units: pmol/L x min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58
Table 12. Plasma GLP-1 concentrations during the oral glucose tolerance tests for each subject. 
            Time 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 0 8.1 22.7 14.3 15.5 43.4 - 49.9 78.0 124.0 83.9 48.9 
 
30 62.1 31.1 15.5 15.5 52.6 - 88.4 63.7 95.7 119.9 60.5 
 
60 41.3 15.5 69.1 23.2 73.4 - 77.9 76.5 98.6 100.4 64.0 
 
90 20.2 32.0 15.5 27.7 62.4 - 80.5 104.0 97.5 66.6 56.3 
 
120 200.0 35.7 15.5 27.0 15.5 - 90.0 100.1 91.7 85.2 73.4 
Day 1 0 15.5 15.5 15.5 31.2 31.0 - 15.5 88.5 100.8 73.9 43.1 
 
30 46.1 22.1 20.4 39.1 40.9 - 110.2 134.0 102.8 75.2 65.6 
 
60 15.5 15.5 51.0 47.7 30.1 - 89.2 102.9 84.4 89.4 58.4 
 
90 35.6 47.3 23.9 39.4 71.7 - 102.4 87.7 85.5 76.1 63.3 
 
120 43.8 15.5 15.5 49.5 15.5 - 81.0 103.3 93.7 119.1 59.7 
Day 7 0 15.5 48.0 15.5 41.5 15.4 - 85.9 93.4 91.2 126.6 59.2 
 
30 42.7 51.1 29.4 17.4 40.9 - 97.5 101.7 120.5 95.5 66.3 
 
60 31.1 43.1 20.7 15.5 16.7 - 102.0 87.3 92.3 93.3 55.8 
 
90 61.9 15.5 8.4 16.6 15.5 - 102.3 113.2 91.0 100.4 58.3 
 
120 17.2 28.8 15.5 15.5 21.7 - 114.4 94.0 95.3 100.4 55.9 
Units: pmol/L 
 
 
 
 
 
Table 13. GLP-1 area above baseline for each subject. 
 801 802 803 804 805 806 807 808 809 810 Mean 
IPE 6537 684 2570 1067 2314 - 4396 1456 0 1564 2287 
Day 1 2245 1631 2122 1621 1922 - 11050 2204 32 1509 2704 
Day 7 3628 65 560 0 928 - 2241 959 976 0 1040 
Units: pmol/L x min 
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Table 14. Oxygen consumption during 5 days of exercise for each subject. 
Subject Day 1 Day 2 Day 3 Day 4 Day 5 
801 45.3 42.5 42.5 cart error 44.0 
802 40.0 40.4 40.4 cart error 42.4 
803 41.1 38.1 38.1 42.1 43.1 
804 41.9 43.6 43.6 42.9 42.5 
805 43.3 42.0 42.0 43.9 42.2 
806 35.1 34.7 34.7 36.5 34.8 
807 39.3 37.6 37.6 35.5 35.9 
808 42.7 42.1 42.1 42.2 43.1 
809 34.6 37.6 37.6 34.6 38.2 
801 37.6 37.0 37.0 41.5 38.9 
Mean 40.1 39.6 39.6 39.9 40.8 
          Units: ml/kg/min 
 
 
 
 
 
Table 15. Oxygen consumption during 5 days of exercise for each subject. 
 Day 1 Day 2 Day 3 Day 4 Day 5 
801 80.9 75.7 76.0 cart error 78.4 
802 71.7 72.5 74.3 cart error 76.5 
803 76.9 70.7 74.1 79.0 80.9 
804 75.4 78.9 81.6 77.4 76.6 
805 73.3 70.9 68.0 74.4 71.2 
806 68.4 67.7 69.7 71.6 68.0 
807 74.9 71.3 61.3 67.1 67.8 
808 74.7 73.6 64.1 74.0 75.7 
809 63.8 69.9 60.4 63.8 50.7 
801 70.2 68.9 71.4 78.1 72.9 
Mean 73.0 72.0 70.1 73.2 74.2 
      Units: Percent of VO2peak 
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Table 16. Three-day diet record for each subject. 
 Day 1 Day 2 Day 3 
Subject CHO Fat Protein kcal CHO Fat Protein kcal CHO Fat Protein kcal 
801 299 121 168 2889 376 116 136 3019 328 111 127 2746 
802 432 78 76 2683 378 62 84 2369 318 96 138 2648 
803 210 35 37 1597 347 115 142 3515 339 90 90 2484 
804 291 160 198 3483 423 151 187 4104 444 158 290 4581 
805 439 97 110 3056 380 83 107 2697 319 109 124 2747 
Male 334.2 98 118 2742 381 105 131 3141 350 113 154 3041 
806 - - - - - - - - - - - - 
807 291 62 82 2498 234 33 52 1454 209 35 57 1349 
808 285 106 161 2707 241 46 62 1670 279 73 76 1972 
809 452 30 88 2379 282 119 95 2568 307 96 77 2363 
810 374 69 94 2417 419 62 77 2491 391 81 85 2593 
Female 351 67 106 2500 294 65 72 2046 297 71 74 2069 
Mean 341 84 113 2634 342 88 105 2654 326 94 118 2609 
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